Comparing COVID drugs from Pfizer and Merck — vaccines still critical

COVID drugs pfizer merck

Pharmaceutical giants Pfizer and Merck have developed new COVID-19 drugs that could become a part of the tools used by physicians to treat COVID. Because of the importance of these drugs, both companies are seeking Emergency Use Authorizations (EUA) from the US FDA to get them in the hands of physicians as quickly as possible.

I have previously written about the Merck drug, molnupiravir, which will go by the trade name of Lagevrio. The Pfizer drug is called PF-07321332, with the trade name Paxlovid. Both drugs are purpose-developed anti-viral medications that have shown strong effectiveness against SARS-CoV-2, the virus that causes COVID-19. These are real antiviral drugs that were developed to treat COVID-19, unlike horse dewormers that have no effect against COVID-19.

This article will be in the form of a simple chart so that you can quickly see the advantages and disadvantages of both Pfizer and Merck COVID-19 drugs. I hope you find this helpful, and drop a note in the comments if you want me to add or change any information.

Continue reading “Comparing COVID drugs from Pfizer and Merck — vaccines still critical”